Cancer Quality Measures
The Samuel Oschin Comprehensive Cancer Institute aims to deliver the highest quality care to all our cancer patients. We constantly strive to follow the latest evidence-based guidelines that will result in the best outcomes for our patients. The patient satisfaction scores listed below show a significant percentage of our patients would recommend us to their family and friends as their provider of choice for cancer care.
To demonstrate our commitment to quality care, the cancer institute is accredited by the Commission on Cancer and participates in monitoring care associated with the quality-of-care guidelines for cancer care endorsed by the Commission on Cancer, the National Quality Forum, the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
These quality-of-care guidelines include the following:
- Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer.
- Tamoxifen or third-generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with T1cN0M0 or stage IB-III hormone receptor positive breast cancer.
- Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes.
- Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.
- Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0 or stage IB-III hormone receptor negative breast cancer.
- At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
- Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer.
- Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0 or Stage III; or postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0 or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer.
For diagnosis year 2015, Cedars-Sinai’s performance with evidence-based guidelines for cancer care for select cancer/tumor sites is presented below. (Data provided by the National Cancer Database.)